These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 28807635)

  • 1. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Gekkieva M; Barnes E; Das Gupta A; Wenzel A; Pearce I;
    Ophthalmology; 2017 Dec; 124(12):1778-1787. PubMed ID: 28807635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
    Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.
    Campochiaro PA; Hafiz G; Mir TA; Scott AW; Solomon S; Zimmer-Galler I; Sodhi A; Duh E; Ying H; Wenick A; Shah SM; Do DV; Nguyen QD; Kherani S; Sophie R
    Ophthalmology; 2015 Jul; 122(7):1426-37. PubMed ID: 25972260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study.
    Wei W; Weisberger A; Zhu L; Cheng Y; Liu C;
    Ophthalmol Retina; 2020 Jan; 4(1):57-66. PubMed ID: 31902472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
    Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
    Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
    Song S; Yu X; Zhang P; Gu X; Dai H
    BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.
    Pielen A; Mirshahi A; Feltgen N; Lorenz K; Korb C; Junker B; Schaefer C; Zwiener I; Hattenbach LO;
    Acta Ophthalmol; 2015 Feb; 93(1):e29-37. PubMed ID: 25042729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
    Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Boscia F; Gerding H; Monés J; Tadayoni R; Priglinger S; Wenzel A; Barnes E; Pilz S; Stubbings W; Pearce I;
    Ophthalmology; 2016 May; 123(5):1101-11. PubMed ID: 26896124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.
    Berger A; Sheidow T; Cruess AF; Arbour JD; Courseau AS; de Takacsy F
    Can J Ophthalmol; 2015 Jun; 50(3):209-16. PubMed ID: 26040221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.
    Campochiaro PA; Sophie R; Pearlman J; Brown DM; Boyer DS; Heier JS; Marcus DM; Feiner L; Patel A;
    Ophthalmology; 2014 Jan; 121(1):209-219. PubMed ID: 24112944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B).
    Hattenbach LO; Feltgen N; Bertelmann T; Schmitz-Valckenberg S; Berk H; Eter N; Lang GE; Rehak M; Taylor SR; Wolf A; Weiss C; Paulus EM; Pielen A; Hoerauf H;
    Acta Ophthalmol; 2018 Feb; 96(1):e10-e18. PubMed ID: 28251811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
    Thach AB; Yau L; Hoang C; Tuomi L
    Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study.
    Hoerauf H; Feltgen N; Weiss C; Paulus EM; Schmitz-Valckenberg S; Pielen A; Puri P; Berk H; Eter N; Wiedemann P; Lang GE; Rehak M; Wolf A; Bertelmann T; Hattenbach LO;
    Am J Ophthalmol; 2016 Sep; 169():258-267. PubMed ID: 27163237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients.
    Kamei M; Terasaki H; Yoshimura N; Shiraga F; Ogura Y; Grotzfeld AS; Pilz S; Ishibashi T
    Acta Ophthalmol; 2017 Feb; 95(1):e29-e35. PubMed ID: 27654837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema.
    Ishibashi T; Li X; Koh A; Lai TY; Lee FL; Lee WK; Ma Z; Ohji M; Tan N; Cha SB; Shamsazar J; Yau CL;
    Ophthalmology; 2015 Jul; 122(7):1402-15. PubMed ID: 25983216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema.
    Goel S; Kumar A; Ravani RD; Chandra P; Chandra M; Kumar V
    Indian J Ophthalmol; 2019 Jul; 67(7):1105-1108. PubMed ID: 31238421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.